Katie Meehan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katie Meehan has a total of 626 co-authors. Here are the top co-authors by number of shared publications:
- Wendy Naomi Erber
School of Biomedical Sciences, The University of Western Australia, Crawley, Australia
8 shared publications Adam Rainczuk
Prince Henry's Institute, Clayton, Victoria, Australia
5 shared publications- Andrew Redfern
Harry Perkins Institute of Medical Research, 5 Robin Warren Dr., Murdoch, WA 6150, Australia
5 shared publications Bob Mirzai
School of Biomedical Sciences, University of Western Australia, Perth, Australia
5 shared publications- Jason Ying Kuen Chan
Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China
5 shared publications - Lisa J. Spalding
Harry Perkins Institute of Medical Research, 5 Robin Warren Dr., Murdoch, WA 6150, Australia
5 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in BJU International
Continuous vs stent‐removal antibiotic prophylaxis after cystectomy: a retrospective analysis
Objectives: To compare the efficacy and microbiological consequences of continuous prophylaxis (CP) vs stent‐removal prophylaxis (SRP) in patients undergoing cystectomy with urinary diversion. Patients and Methods: This single‐centre retrospective cohort study included 223 patients undergoing cystectomy with urinary diversion from 2015 to 2024. All patients received identical perioperative intravenous prophylaxis (cefazolin and metronidazole for up to 48 h). Groups were defined by the subsequent oral strategy: SRP ( n = 119), a 3‐day course of amoxicillin‐clavulanate around stent removal, vs CP ( n = 104), amoxicillin‐clavulanate given continuously from completion of intravenous prophylaxis until the day after stent removal. Primary endpoints included surgical site infection (SSI), urinary tract infection (UTI), readmission rates, and new isolation of organisms not covered by the prophylactic regimen. Multivariable logistic and negative binomial regression models adjusted for pre‐specified confounders. Results: The CP group had a higher median Charlson Comorbidity Index (4 vs 3, P = 0.023). Despite a median antibiotic duration of 16.0 (CP) vs 7.0 days (SRP) ( P < 0.001), no significant differences were observed in UTI (27.9% vs 31.9%, P = 0.6), SSI (28.8% vs 28.6%, P > 0.9), or 30‐day readmission (26.0% vs 29.4%, P = 0.7). CP was associated with significantly higher isolation of new organisms not covered by the prophylactic regimen (32.7% vs 19.3%, P = 0.031) and new Pseudomonas aeruginosa isolation (15.4% vs 2.5%, P < 0.001). CP was associated with postoperative Pseudomonas isolation after adjustment using Firth's penalised logistic regression (odds ratio 5.50, 95% confidence interval 1.77–22.36, P = 0.002). Conclusion: Continuous prophylaxis was not associated with fewer infectious complications or readmissions but was associated with increased isolation of organisms not covered by prophylaxis, particularly P. aeruginosa . Given the non‐randomised historical before–after design, non‐overlapping study periods, and baseline differences, these findings remain hypothesis‐generating.
- 16 November 2026
- Published by Wiley in BJU International
Open AccessContinuous vs stent‐removal antibiotic prophylaxis after cystectomy: a retrospective analysis
Objectives: To compare the efficacy and microbiological consequences of continuous prophylaxis (CP) vs stent‐removal prophylaxis (SRP) in patients undergoing cystectomy with urinary diversion. Patients and Methods: This single‐centre retrospective cohort study included 223 patients undergoing cystectomy with urinary diversion from 2015 to 2024. All patients received identical perioperative intravenous prophylaxis (cefazolin and metronidazole for up to 48 h). Groups were defined by the subsequent oral strategy: SRP ( n = 119), a 3‐day course of amoxicillin‐clavulanate around stent removal, vs CP ( n = 104), amoxicillin‐clavulanate given continuously from completion of intravenous prophylaxis until the day after stent removal. Primary endpoints included surgical site infection (SSI), urinary tract infection (UTI), readmission rates, and new isolation of organisms not covered by the prophylactic regimen. Multivariable logistic and negative binomial regression models adjusted for pre‐specified confounders. Results: The CP group had a higher median Charlson Comorbidity Index (4 vs 3, P = 0.023). Despite a median antibiotic duration of 16.0 (CP) vs 7.0 days (SRP) ( P < 0.001), no significant differences were observed in UTI (27.9% vs 31.9%, P = 0.6), SSI (28.8% vs 28.6%, P > 0.9), or 30‐day readmission (26.0% vs 29.4%, P = 0.7). CP was associated with significantly higher isolation of new organisms not covered by the prophylactic regimen (32.7% vs 19.3%, P = 0.031) and new Pseudomonas aeruginosa isolation (15.4% vs 2.5%, P < 0.001). CP was associated with postoperative Pseudomonas isolation after adjustment using Firth's penalised logistic regression (odds ratio 5.50, 95% confidence interval 1.77–22.36, P = 0.002). Conclusion: Continuous prophylaxis was not associated with fewer infectious complications or readmissions but was associated with increased isolation of organisms not covered by prophylaxis, particularly P. aeruginosa . Given the non‐randomised historical before–after design, non‐overlapping study periods, and baseline differences, these findings remain hypothesis‐generating.
- Open Access
Exploring Traditional Breast Cancer Risk Genes Among Aboriginal and Torres Strait Islander Women
Background: Germline pathogenic variants in BRCA1/2 increase breast and ovarian cancer risk, but their prevalence in Aboriginal and Torres Strait Islander (herein referred to as Aboriginal) families has never been studied. Consequently, their contribution to breast cancer in this population is unknown. Methods: This retrospective cohort study included 259 Aboriginal women and 789 age- and remoteness-matched non-Aboriginal women diagnosed with breast cancer (2001–2016). We assessed family history, genetic service referral and testing rates, and pathogenic variant rates in the context of testing access. Results: Family history data were available for more Aboriginal than non-Aboriginal cases (46% vs. 34%, p < 0.001), with no difference in reported first-degree relatives with breast (22.5% vs. 22.4%, p = 0.98) or ovarian cancer (4.2% vs. 2.2%, p = 0.29). Similar proportions were referred to genetic services for testing eligibility (5.4% vs. 7.2%, p = 0.392). Of those referred, similar proportions were offered testing (86% vs. 81%, p = 0.66). Across the full cohort, BRCA1/2 pathogenic variants were detected in 0.77% of Aboriginal versus 2.4% of non-Aboriginal women (p = 0.127); any pathogenic gene variant was detected in 0.77% versus 3.0% (p = 0.039). Conclusions: Pathogenic genetic variants were detected less frequently in Aboriginal women, although, in keeping with international clinical practice, most women diagnosed with breast cancer were not tested. Given that only a small proportion of the cohort underwent germline testing, this study cannot distinguish whether the lower detection rate reflects a genuinely lower population level prevalence of pathogenic variants or differences in historical referral, selection, and testing practices. These findings are hypothesis-generating and require validation in larger Australian Aboriginal studies including unselected populations with whole-population testing data.
Open AccessExploring Traditional Breast Cancer Risk Genes Among Aboriginal and Torres Strait Islander Women
Background: Germline pathogenic variants in BRCA1/2 increase breast and ovarian cancer risk, but their prevalence in Aboriginal and Torres Strait Islander (herein referred to as Aboriginal) families has never been studied. Consequently, their contribution to breast cancer in this population is unknown. Methods: This retrospective cohort study included 259 Aboriginal women and 789 age- and remoteness-matched non-Aboriginal women diagnosed with breast cancer (2001–2016). We assessed family history, genetic service referral and testing rates, and pathogenic variant rates in the context of testing access. Results: Family history data were available for more Aboriginal than non-Aboriginal cases (46% vs. 34%, p < 0.001), with no difference in reported first-degree relatives with breast (22.5% vs. 22.4%, p = 0.98) or ovarian cancer (4.2% vs. 2.2%, p = 0.29). Similar proportions were referred to genetic services for testing eligibility (5.4% vs. 7.2%, p = 0.392). Of those referred, similar proportions were offered testing (86% vs. 81%, p = 0.66). Across the full cohort, BRCA1/2 pathogenic variants were detected in 0.77% of Aboriginal versus 2.4% of non-Aboriginal women (p = 0.127); any pathogenic gene variant was detected in 0.77% versus 3.0% (p = 0.039). Conclusions: Pathogenic genetic variants were detected less frequently in Aboriginal women, although, in keeping with international clinical practice, most women diagnosed with breast cancer were not tested. Given that only a small proportion of the cohort underwent germline testing, this study cannot distinguish whether the lower detection rate reflects a genuinely lower population level prevalence of pathogenic variants or differences in historical referral, selection, and testing practices. These findings are hypothesis-generating and require validation in larger Australian Aboriginal studies including unselected populations with whole-population testing data.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Bar charts showing significantly more Aboriginal females live in areas of greatest socioeconomic disadvantage and outside the greater metropolitan area
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Bar charts showing significantly more Aboriginal females live in areas of greatest socioeconomic disadvantage and outside the greater metropolitan area
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Analysis of co-variates for Aboriginal females and females from TCGA
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Analysis of co-variates for Aboriginal females and females from TCGA
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Immune-biology data for Aboriginal females and females from TCGA with breast cancer
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Immune-biology data for Aboriginal females and females from TCGA with breast cancer
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (7) , 1167-1176
Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Background: Despite access to universal health care, Aboriginal and Torres Strait Islander females (hereafter respectfully referred to as Aboriginal) in Australia have higher breast cancer incidence and mortality rates. We investigated the factors contributing to these survival disparities. Methods: Aboriginal females (n = 395; 0.7%) and non-Aboriginal females (n = 57,618; 99.3%) with breast cancer were identified from Victoria, Australia. Clinical, pathologic, demographic, and socioeconomic variables were analyzed. Endpoints were all-cause and breast cancer–specific mortality. HRs were estimated using Cox regression. Stromal tumor–infiltrating lymphocytes were evaluated from a subset of Aboriginal females and compared with females in The Cancer Genome Atlas. Results: Registry data revealed that Aboriginal females were younger (P < 0.001), had more advanced stage disease (P = 0.007), and were more likely to live in nonmetropolitan areas (P < 0.001) and in areas of greater disadvantage (P < 0.001) compared with other females at diagnosis. Age-adjusted multivariate analysis revealed a higher all-cause mortality risk (HR 1.27; 95% confidence interval, 1–1.61) for Aboriginal females, but this risk diminished for breast cancer–specific mortality and after adjustment for stage and grade. Breast cancers from Aboriginal females had significantly reduced stromal tumor–infiltrating lymphocytes in the luminal and triple-negative subtypes compared with The Cancer Genome Atlas. Conclusions: Mortality for females with breast cancer was influenced by socioeconomic, geographic, and clinical factors. Notably, Aboriginal females with tumor features typically associated with favorable outcomes experienced poorer outcomes. The reduced immune infiltrate warrants further investigation. Impact: These findings highlight the need to address socioeconomic inequities and ensure culturally safe cancer care. Further research should explore biological and environmental factors influencing outcomes for Australian Aboriginal females.
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (7) , 1167-1176
Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer
Background: Despite access to universal health care, Aboriginal and Torres Strait Islander females (hereafter respectfully referred to as Aboriginal) in Australia have higher breast cancer incidence and mortality rates. We investigated the factors contributing to these survival disparities. Methods: Aboriginal females (n = 395; 0.7%) and non-Aboriginal females (n = 57,618; 99.3%) with breast cancer were identified from Victoria, Australia. Clinical, pathologic, demographic, and socioeconomic variables were analyzed. Endpoints were all-cause and breast cancer–specific mortality. HRs were estimated using Cox regression. Stromal tumor–infiltrating lymphocytes were evaluated from a subset of Aboriginal females and compared with females in The Cancer Genome Atlas. Results: Registry data revealed that Aboriginal females were younger (P < 0.001), had more advanced stage disease (P = 0.007), and were more likely to live in nonmetropolitan areas (P < 0.001) and in areas of greater disadvantage (P < 0.001) compared with other females at diagnosis. Age-adjusted multivariate analysis revealed a higher all-cause mortality risk (HR 1.27; 95% confidence interval, 1–1.61) for Aboriginal females, but this risk diminished for breast cancer–specific mortality and after adjustment for stage and grade. Breast cancers from Aboriginal females had significantly reduced stromal tumor–infiltrating lymphocytes in the luminal and triple-negative subtypes compared with The Cancer Genome Atlas. Conclusions: Mortality for females with breast cancer was influenced by socioeconomic, geographic, and clinical factors. Notably, Aboriginal females with tumor features typically associated with favorable outcomes experienced poorer outcomes. The reduced immune infiltrate warrants further investigation. Impact: These findings highlight the need to address socioeconomic inequities and ensure culturally safe cancer care. Further research should explore biological and environmental factors influencing outcomes for Australian Aboriginal females.
- Open Access
- 15 March 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (10) , 2473-2480
Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer
BackgroundIdentifying patients at high risk for colorectal cancer recurrence is essential for improving prognosis. In the postoperative period, circulating tumour DNA (ctDNA) has been demonstrated as a significant prognostic indicator of recurrence. These results have been obtained under the strict rigours of clinical trials, but not validated in a real-world setting using in-house testing. We report the outcomes of locally performed postoperative ctDNA testing conducted during routine clinical care and the association with the recurrence of colorectal cancer. MethodsWe recruited 36 consecutive patients with newly diagnosed colorectal cancer between 2018 and 2020. Postoperative plasma samples were collected at the first outpatient review following resection. Tumour-informed ctDNA analysis was performed using droplet digital polymerase chain reaction or targeted next-generation sequencing. ResultsAt the time of surgery, there were 24 patients (66.7%) with localized cancer, nine (25%) with nodal spread, and three (8.3%) with metastatic disease. The median time from surgery to plasma sample donation was 22 days (IQR 20-28 days). At least one somatic mutation was identified in primary tumour tissue for 28 (77.8%) patients. Postoperative ctDNA was detected in five patients (13.9%). The median duration of follow-up was 32.0 months (IQR 27.2-38.1 months). Two patients (5.56%) developed metastatic recurrence. However, neither had detectable postoperative ctDNA. There were no instances of loco-regional recurrence. ConclusionAnalysis of postoperative ctDNA testing can be performed locally, however this study did not reproduce the adverse association between detectable postoperative ctDNA and the development of colorectal cancer recurrence seen in clinical trials.
- 15 March 2023
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (10) , 2473-2480
Open AccessLocally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer
BackgroundIdentifying patients at high risk for colorectal cancer recurrence is essential for improving prognosis. In the postoperative period, circulating tumour DNA (ctDNA) has been demonstrated as a significant prognostic indicator of recurrence. These results have been obtained under the strict rigours of clinical trials, but not validated in a real-world setting using in-house testing. We report the outcomes of locally performed postoperative ctDNA testing conducted during routine clinical care and the association with the recurrence of colorectal cancer. MethodsWe recruited 36 consecutive patients with newly diagnosed colorectal cancer between 2018 and 2020. Postoperative plasma samples were collected at the first outpatient review following resection. Tumour-informed ctDNA analysis was performed using droplet digital polymerase chain reaction or targeted next-generation sequencing. ResultsAt the time of surgery, there were 24 patients (66.7%) with localized cancer, nine (25%) with nodal spread, and three (8.3%) with metastatic disease. The median time from surgery to plasma sample donation was 22 days (IQR 20-28 days). At least one somatic mutation was identified in primary tumour tissue for 28 (77.8%) patients. Postoperative ctDNA was detected in five patients (13.9%). The median duration of follow-up was 32.0 months (IQR 27.2-38.1 months). Two patients (5.56%) developed metastatic recurrence. However, neither had detectable postoperative ctDNA. There were no instances of loco-regional recurrence. ConclusionAnalysis of postoperative ctDNA testing can be performed locally, however this study did not reproduce the adverse association between detectable postoperative ctDNA and the development of colorectal cancer recurrence seen in clinical trials.
- Open Access
- 18 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14336
Fluid Biomarkers in HPV and Non-HPV Related Oropharyngeal Carcinomas: From Diagnosis and Monitoring to Prognostication—A Systematic Review
Biomarkers are crucial in oncology, from detection and monitoring to guiding management and predicting treatment outcomes. Histological assessment of tissue biopsies is currently the gold standard for oropharyngeal cancers, but is technically demanding, invasive, and expensive. This systematic review aims to review current markers that are detectable in biofluids, which offer promising non-invasive alternatives in oropharyngeal carcinomas (OPCs). A total of 174 clinical trials from the PubMed search engine in the last 5 years were identified and screened by 4 independent reviewers. From these, 38 eligible clinical trials were found and subsequently reviewed. The biomarkers involved, categorized by human papillomavirus (HPV)-status, were further divided according to molecular and cellular levels. Recent trials investigating biomarkers for both HPV-positive and HPV-negative OPCs have approaches from various levels and different biofluids including plasma, oropharyngeal swabs, and oral rinse. Promising candidates have been found to aid in detection, staging, and predicting prognosis, in addition to well-established factors including HPV-status, drinking and smoking status. These studies also emphasize the possibility of enhancing prediction results and increasing statistical significance by multivariate analyses. Liquid biopsies offer promising assistance in enhancing personalized medicine for cancer treatment, from lowering barriers towards early screening, to facilitating de-escalation of treatment. However, further research is needed, and the combination of liquid biopsies with pre-existing methods, including in vivo imaging and invasive techniques such as neck dissections, could also be explored in future trials.
- 18 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14336
Open AccessFluid Biomarkers in HPV and Non-HPV Related Oropharyngeal Carcinomas: From Diagnosis and Monitoring to Prognostication—A Systematic Review
Biomarkers are crucial in oncology, from detection and monitoring to guiding management and predicting treatment outcomes. Histological assessment of tissue biopsies is currently the gold standard for oropharyngeal cancers, but is technically demanding, invasive, and expensive. This systematic review aims to review current markers that are detectable in biofluids, which offer promising non-invasive alternatives in oropharyngeal carcinomas (OPCs). A total of 174 clinical trials from the PubMed search engine in the last 5 years were identified and screened by 4 independent reviewers. From these, 38 eligible clinical trials were found and subsequently reviewed. The biomarkers involved, categorized by human papillomavirus (HPV)-status, were further divided according to molecular and cellular levels. Recent trials investigating biomarkers for both HPV-positive and HPV-negative OPCs have approaches from various levels and different biofluids including plasma, oropharyngeal swabs, and oral rinse. Promising candidates have been found to aid in detection, staging, and predicting prognosis, in addition to well-established factors including HPV-status, drinking and smoking status. These studies also emphasize the possibility of enhancing prediction results and increasing statistical significance by multivariate analyses. Liquid biopsies offer promising assistance in enhancing personalized medicine for cancer treatment, from lowering barriers towards early screening, to facilitating de-escalation of treatment. However, further research is needed, and the combination of liquid biopsies with pre-existing methods, including in vivo imaging and invasive techniques such as neck dissections, could also be explored in future trials.
- Open Access
The Role of Arginine Metabolism in Oral Tongue Squamous Cell Carcinoma
Early diagnosis and treatment do not prevent the high morbidity and poor prognosis of oral tongue squamous cell carcinoma (TSCC). Earlier studies have shown that ARG1 signaling is deregulated in TSCC. Here, we investigated the complexity of ARG1 metabolism in this cancer subsite to appreciate the therapeutic potential of this potential biological vulnerability. Various functional studies show that ARG1 overexpression in oral cancer cells inhibits cell proliferation and invasion compared with controls. Further, RNA-sequencing revealed numerous differentially expressed genes (DEGs) and associated networks were dysregulated by ARG1 overexpression, including hypoxia-inducible factor (HIFα) signaling, the natural killer cell signaling pathway and interferon signaling. Our work provides a foundation for understanding the mechanism of action of disrupted arginine metabolism in oral tongue squamous cell carcinoma. This may impact the community for developing further therapeutic approaches.
Open AccessThe Role of Arginine Metabolism in Oral Tongue Squamous Cell Carcinoma
Early diagnosis and treatment do not prevent the high morbidity and poor prognosis of oral tongue squamous cell carcinoma (TSCC). Earlier studies have shown that ARG1 signaling is deregulated in TSCC. Here, we investigated the complexity of ARG1 metabolism in this cancer subsite to appreciate the therapeutic potential of this potential biological vulnerability. Various functional studies show that ARG1 overexpression in oral cancer cells inhibits cell proliferation and invasion compared with controls. Further, RNA-sequencing revealed numerous differentially expressed genes (DEGs) and associated networks were dysregulated by ARG1 overexpression, including hypoxia-inducible factor (HIFα) signaling, the natural killer cell signaling pathway and interferon signaling. Our work provides a foundation for understanding the mechanism of action of disrupted arginine metabolism in oral tongue squamous cell carcinoma. This may impact the community for developing further therapeutic approaches.
- Open Access
Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer
Breast cancer is the leading cause of cancer death in women. The majority of these deaths are due to disease metastasis, in which cancer cells disseminate to multiple organs and disrupt vital physiological functions. It is widely accepted that breast cancer cells secrete extracellular vesicles (EVs), which contain dynamic molecular cargo that act as versatile mediators of intercellular communication. Therefore, Evs. secreted by breast cancer cells could be involved in the development of metastatic disease and resistance to treatment. Moreover, changes in EV cargo could reflect the effects of therapy on their parent tumor cells. The aim of this feasibility study was to quantitatively profile the proteomes of Evs. isolated from blood samples taken from treatment sensitive and resistant metastatic breast cancer patients to identify proteins associated with responses. Three serial blood samples were collected from three patients with metastatic breast cancer receiving systemic therapy including a responder, a non-responder, and a mixed-responder. Evs. were isolated from plasma using size exclusion chromatography and their protein cargo was prepared for tandem mass tag (TMT)-labelling and quantitative analyses using two-dimensional high-performance liquid chromatography followed by tandem mass spectrometry. After filtering, we quantitatively identified 286 proteins with high confidence using a q value of 0.05. Of these, 149 were classified as EV associated candidate proteins and 137 as classical, high abundant plasma proteins. After comparing EV protein abundance between the responder and non-responder, we identified 35 proteins with unique de-regulated abundance patterns that was conserved at multiple time points. We propose that this proof-of-concept approach can be used to identify proteins which have potential as predictors of metastatic breast cancer response to treatment.
Open AccessDynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer
Breast cancer is the leading cause of cancer death in women. The majority of these deaths are due to disease metastasis, in which cancer cells disseminate to multiple organs and disrupt vital physiological functions. It is widely accepted that breast cancer cells secrete extracellular vesicles (EVs), which contain dynamic molecular cargo that act as versatile mediators of intercellular communication. Therefore, Evs. secreted by breast cancer cells could be involved in the development of metastatic disease and resistance to treatment. Moreover, changes in EV cargo could reflect the effects of therapy on their parent tumor cells. The aim of this feasibility study was to quantitatively profile the proteomes of Evs. isolated from blood samples taken from treatment sensitive and resistant metastatic breast cancer patients to identify proteins associated with responses. Three serial blood samples were collected from three patients with metastatic breast cancer receiving systemic therapy including a responder, a non-responder, and a mixed-responder. Evs. were isolated from plasma using size exclusion chromatography and their protein cargo was prepared for tandem mass tag (TMT)-labelling and quantitative analyses using two-dimensional high-performance liquid chromatography followed by tandem mass spectrometry. After filtering, we quantitatively identified 286 proteins with high confidence using a q value of 0.05. Of these, 149 were classified as EV associated candidate proteins and 137 as classical, high abundant plasma proteins. After comparing EV protein abundance between the responder and non-responder, we identified 35 proteins with unique de-regulated abundance patterns that was conserved at multiple time points. We propose that this proof-of-concept approach can be used to identify proteins which have potential as predictors of metastatic breast cancer response to treatment.